Servier
59
11
17
29
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 35/100
3.4%
2 terminated/withdrawn out of 59 trials
93.5%
+7.0% vs industry average
20%
12 trials in Phase 3/4
7%
2 of 29 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (59)
Improving Goal Directed Medical Therapy for Device Clinic Patients With Reduced EF at UOHI: a QI Initiative (VIGILANT)
Role: collaborator
S243249 Monotherapy in Patients With Relapsed or Refractory Acute Leukemia With a KMT2A or NUP98 Translocation or Relapsed or Refractory AML With NPM1c Mutation
Role: lead
ViCToRy: Vorasidenib in Combination With Tumor Specific Peptide Vaccine for Recurrent IDH1 Mutant Lower Grade Gliomas
Role: collaborator
Liposomal iRInotecan, Carboplatin or oXaliplatin for Esophagogastric Cancer
Role: collaborator
A Treatment Study Protocol for Participants 0-45 Years With Acute Lymphoblastic Leukaemia
Role: collaborator
Vorasidenib Expanded Access Program
Role: lead
Oxaliplatin ± Nivolumab in Combination With Trifluridine/Tipiracil or 5-fluorouracile in Frail Patients With Advanced, Recurrent or Metastatic Gastric, Oesophageal or Gastroesophageal Junction Cancer
Role: collaborator
A Study to Evaluate S241656 Alone or in Combination in Participants With Selected Myeloid Malignancies
Role: lead
Treatment of Newly Diagnosed Acute Lymphoblastic Leukemia in Children and Adolescents
Role: collaborator
Ivosidenib as Post-HSCT Maintenance for AML
Role: collaborator
Total Therapy XVII for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia and Lymphoma
Role: collaborator
Phase 3 Study of Vorasidenib (S095032/AG-881) in Asian Participants With Residual or Recurrent Grade 2 Glioma With an IDH1 orIDH2 Mutation
Role: lead
TAS102 in Patients With ER-positive, HER2-negative Advanced Breast Cancer
Role: collaborator
Personalized Medicine for Advanced Biliary Cancer Patients
Role: collaborator
Venetoclax Basket Trial for High Risk Hematologic Malignancies
Role: collaborator
CalPeg for Newly Diagnosed Acute Lymphoblastic Leukemia (ALL)
Role: collaborator
Exploiting Circulating Tumour DNA to Intensify the Postoperative Treatment Resected Colon Cancer Patients
Role: collaborator
Metabolically Optimized, Non-cytotoxic Low Dose Weekly Decitabine/Venetoclax in MDS and AML
Role: collaborator
Safety of Trifluridine/Tipiracil in Patients With Dihydropyrimidine Dehydrogenase Deficiency Diagnosed With Metastatic Colorectal or Gastroesophageal Cancer
Role: collaborator
A Phase 2 Study of Ivosidenib in Previously Treated Japanese Subjects With Nonresectable or Metastatic Cholangiocarcinoma With an IDH1 Mutation
Role: lead